Beyond Public Health and Medicine: The Potential Impact of GLP-1s and Other Incretin Mimetic Medications on Greenhouse Gas Emissions

Manufacturing and use of pharmaceuticals is responsible for nearly 20% of US health care's greenhouse gas footprint. As highly effective weight-loss medications such as incretin mimetics become widely prescribed, it is important to understand environmental implications. More than 33.5 million Americans have tried incretin mimetic medications (IMMs), and nearly 30 million are projected to be consistent users by 2030. This article examines the broader potential implications of glucagon-like peptide-1 and other IMMs on climate change. We conducted a preliminary and speculative carbon footprint of IMMs using a life cycle assessment approach. Our findings suggest widespread IMM use could reduce greenhouse gas emissions by decreasing caloric consumption, food production, and health care activities, leading to a maximum estimated reduction of 760 kg CO2e/person/year. This reduction would be greater than the environmental benefits of switching to electric vehicles or adopting a vegetarian diet. This study highlights the need for more research into potential environmental benefits of IMMs.